Comparative Pharmacology
Head-to-head clinical analysis: MICRODERM versus RETIN A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICRODERM versus RETIN A.
MICRODERM vs RETIN-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICRODERM is a brand name for tretinoin, a retinoid that binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene transcription to promote keratinocyte differentiation, reduce proliferation, and normalize desquamation, thereby decreasing comedone formation and inflammation.
Retin-A (tretinoin) binds to retinoic acid receptors (RARα, RARβ, RARγ) and retinoid X receptors (RXR), modulating gene expression involved in cell differentiation, proliferation, and inflammation. It increases epidermal turnover, reduces comedone formation, and stimulates collagen synthesis.
MICRODERM is not a recognized pharmaceutical agent; no standard dosing information available.
Apply a thin layer to affected areas once daily at bedtime. Initial concentration typically 0.025% cream or 0.01% gel; titrate based on tolerability.
None Documented
None Documented
Terminal elimination half-life is 12 hours (range 10-15 h); requires dose adjustment in renal impairment when CrCl <30 mL/min.
Terminal elimination half-life is approximately 0.5-2 hours for the parent drug. Clinical context: Due to rapid clearance, systemic accumulation is negligible with topical use; effects persist due to retinoid-induced gene expression changes.
Renal excretion accounts for 70% as unchanged drug, biliary/fecal elimination 20%, hepatic metabolism 10%.
After topical application, systemic absorption is minimal. The absorbed fraction is metabolized in the liver via cytochrome P450 enzymes and excreted in bile and urine as glucuronide conjugates. Renal excretion accounts for <1% of the applied dose; fecal excretion of metabolites is the primary route (<5% of applied dose).
Category C
Category C
Topical Retinoid
Topical Retinoid